Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7201-7210 Newer>

The Motley Fool February 25, 2011 Brian Orelli	Minor Delay, Major Missed Opportunity Protalix and Pfizer's Gaucher disease drug gets delayed.
The Motley Fool February 25, 2011 Todd Wenning	Dividend Report Card: Bristol-Myers Squibb How does the pharma giant's dividend stack up?
The Motley Fool February 24, 2011 Brian Orelli	Continuing to Play Me-Too Onglyza is never going to catch Januvia.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
BusinessWeek February 24, 2011 Adi Narayan	From Brewing, an Indian Biotech Is Born In the wake of its deal with Pfizer, Biocon is well positioned to take advantage of the world's increasing diabetes problem.
The Motley Fool February 24, 2011 Brian D. Pacampara	Salix Pharmaceuticals Shares Plunged: What You Need to Know Shares of Salix Pharmaceuticals plummeted more than 20% after the company said it expects the Food and Drug Administration to deny its bid to gain expanded approval for its gastrointestinal antibiotic Xifaxan.
The Motley Fool February 24, 2011 Brian Orelli	Youth in Revolt Against POZEN POZEN fails to get a pediatric extension on its migraine drug.
The Motley Fool February 24, 2011 Brian Orelli	Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%.
The Motley Fool February 24, 2011 Jordan DiPietro	Should You Retire With Merck? Is Merck a good choice for a retirement portfolio?
The Motley Fool February 23, 2011 Anders Bylund	Zix Gets by With the Help of Its Friends Security is hot, and Zix is getting plenty of help from IT giants.
<Older 7201-7210 Newer> Return to current articles.